Production and Characterization of Chimeric Monoclonal Antibodies against Burkholderia pseudomallei and B. mallei Using the DHFR Expression System

Abstract

Burkholderia pseudomallei (BP) and B. mallei (BM) are closely related gram-negative, facultative anaerobic bacteria which cause life-threatening melioidosis in human and glanders in horse, respectively. Our laboratory has previously generated and characterized more than 100 mouse monoclonal antibodies (MAbs) against BP and BM, according to in vitro and in vivo assay. In this study, 3 MAbs (BP7 10B11, BP7 2C6, and BP1 7F7) were selected to develop into chimeric mouse-human monoclonal antibodies (cMAbs) against BP and/or BM. For the stable production of cMAbs, we constructed 4 major different vector systems with a dihydrofolate reductase (DHFR) amplification marker, and optimized transfection/selection conditions in mammalian host cells with the single-gene and/or double-gene expression system. These 3 cMAbs were stably produced by the DHFR double mutant Chinese hamster ovarian (CHO)-DG44 cells. By ELISA and Western blot analysis using whole bacterial antigens treated by heat (65°C/90 min), sodium periodate, and proteinase K, the cMAb BP7 10B11 (cMAb CK1) reacted with glycoproteins (34, 38, 48 kDa in BP; 28, 38, 48 kDa in BM). The cMAb BP7 2C6 (cMAb CK2) recognized surface-capsule antigens with molecular sizes of 38 to 52 kDa, and 200 kDa in BM. The cMAb CK2 was weakly reactive to 14∼28, 200 kDa antigens in BP. The cMAb BP1 7F7 (cMAb CK3) reacted with lipopolysaccharides (38∼52 kDa in BP; 38∼60 kDa in B. thailandensis). Western blot results with the outer surface antigens of the 3 Burkholderia species were consistent with results with the whole Burkholderia cell antigens, suggesting that these immunodominant antigens reacting with the 3 cMAbs were primarily present on the outer surface of the Burkholderia species. These 3 cMAbs would be useful for analyzing the role of the major outer surface antigens in Burkholderia infection.

A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors

“…After searching for VH and VL framework sequences in the ImMunoGeneTics database of human germline sequences, IGHV1-3*01 and IGKV1-12*01 were selected as framework templates. Production and purification of anti-MSLN (HMI323) IgG 1 was performed as previously reported [26].…”

“…The genes for the humanized anti-CD3 antibody were constructed with whole synthesized genes, which were then inserted into the pCI mammalian expression vector (Promega). Production and purification of anti-CD3ε (A15) IgG 1 were performed as previously described [26].…”

An Antibody to the Sixth Ig-like Domain of VCAM-1 Inhibits Leukocyte Transendothelial Migration without Affecting Adhesion

“…After column chromatography, fractions containing Fab were pooled and analyzed by SDS-PAGE and Coomassie blue staining as described previously (46). The production and purification of VCAM-1-D6 IgG was performed as described previously (47).…”

An anti-Gn glycoprotein antibody from a convalescent patient potently inhibits the infection of severe fever with thrombocytopenia syndrome virus

“…The genes encoding the variable heavy chain and variable light chain of Ab10 and MAb4-5[28] were synthesized (Integrated DNA Technologies, GenScript) and fused with human heavy chain constant region gene (IgG 1 ) and human kappa light chain gene, and then cloned into an eukaryotic expression vector, as described previously[63,64]. The expression vectors were transfected into HEK 293F cells.…”